Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumor... Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -2.70935960591 | 4.06 | 4.12 | 3.7501 | 6296 | 3.98958491 | DR |
| 4 | -0.17 | -4.12621359223 | 4.12 | 4.3459 | 3.66 | 6379 | 3.92126505 | DR |
| 12 | -0.38 | -8.77598152425 | 4.33 | 4.804 | 3.66 | 4395 | 4.08355776 | DR |
| 26 | -0.28 | -6.61938534279 | 4.23 | 5.36 | 3.66 | 4483 | 4.22149146 | DR |
| 52 | 0.15 | 3.94736842105 | 3.8 | 5.36 | 3.4101 | 4123 | 4.09996492 | DR |
| 156 | -2.79 | -41.3946587537 | 6.74 | 12.7 | 3.32 | 9894 | 5.70497069 | DR |
| 260 | -16.05 | -80.25 | 20 | 32.04 | 3.32 | 16372 | 13.12106361 | DR |
Trades verzögert
Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto
Auf Echtzeit aktualisieren| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
